Search

Your search keyword '"Frega, Giorgio"' showing total 203 results
Start Over Author "Frega, Giorgio"
203 results on '"Frega, Giorgio"'

1. A reduction in tumor volume exceeding 65% predicts a good histological response to neoadjuvant chemotherapy in patients with Ewing sarcoma

Author

Aso, Ayano, Aiba, Hisaki, Traversari, Matteo, Righi, Alberto, Gambarotti, Marco, Atherley O’Meally, Ahmed, Solou, Konstantina, Cammelli, Silvia, Bordini, Barbara, Cosentino, Monica, Zuccheri, Federica, Dozza, Barbara, Frega, Giorgio, Ibrahim, Toni, Manfrini, Marco, Donati, Davide Maria, and Errani, Costantino

Published
2024
Full Text
View/download PDF

6. Treatment Sequencing and Independent Outcomes of First- and Second-Line Chemotherapy in a Retrospective Series of Patients with Biliary Tract Cancer.

Author

Frega, Giorgio, Palloni, Andrea, Deiana, Chiara, Rizzo, Alessandro, Ricci, Angela Dalia, and Brandi, Giovanni

Subjects
*CANCER chemotherapy, *PATIENTS' attitudes, *CISPLATIN, *SEQUENTIAL analysis, BILIARY tract cancer
Abstract

Background/Objectives: Biliary tract cancers (BTCs) are aggressive neoplasms with limited therapeutic options. The amount of prospective evidence is poor, and limited data are available on the impact of treatment sequencing on survival. Here we report a real-world experience of patients with advanced BTC treated with at least three lines of therapy. We evaluated the impact of sequential treatments, and we further compared the efficacy of Gemcitabine/Cisplatin (GemCis) and mFOLFOX to other first- and second-line chemotherapy regimens, respectively. Methods: Data on 60 patients with locally advanced or metastatic BTC under the care of a single Italian referral hospital and treated with at least three lines of chemotherapy were retrospectively collected. Data from 56 patients were included in the analysis. Survival analyses were performed using R software (v1.2.5042). Results: We compared the outcomes of patients treated according to the "standard" pre-immunotherapy sequence (GemCis and mFOLFOX in the first and second lines, respectively) versus those treated with all other combinations ("control" group). Our analysis did not show significant survival differences between the two groups. However, it should be noted that we selected long-survival patients by including only those who received at least three or more lines of chemotherapy. Focusing on the first-line setting, no significant differences in both mPFS and mOS emerged by comparing GemCis versus other doublets (mainly Gemcitabine/Oxaliplatin). Similarly, mPFS and mOS from second-line treatment did not statistically differ between patients treated with mFOLFOX versus those treated with other regimens (71% chemotherapy doublets). Conclusions: Our series provides real-world outcomes of patients with advanced BTC before the approval of immunotherapy. Even considering the monocentric and retrospective design, our study represents one of the first analyses on the impact of sequential treatment strategies in patients with BTC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications.

Author

Ricci, Angela Dalia, Rizzo, Alessandro, Schirizzi, Annalisa, D'Alessandro, Rosalba, Frega, Giorgio, Brandi, Giovanni, Shahini, Endrit, Cozzolongo, Raffaele, Lotesoriere, Claudio, and Giannelli, Gianluigi

Subjects
BILE duct tumors, CHOLANGIOCARCINOMA, IMMUNOTHERAPY, TREATMENT effectiveness, TUMOR markers, IMMUNE checkpoint inhibitors, SURVIVAL analysis (Biometry)
Abstract

Simple Summary: Treatment options for intrahepatic cholangiocarcinoma (iCCA), a highly malignant tumor with poor prognosis, are limited. Recent developments in immunotherapy and immune checkpoint inhibitors (ICIs) have offered new hope for treating iCCA. However, several issues remain, including the identification of reliable biomarkers of response to ICIs and immune-based combinations. Tumor immune microenvironment (TIME) of these hepatobiliary tumors has been evaluated and is under assessment in order to boost the efficacy of ICIs and to convert these immunologically "cold" tumors to "hot" tumors. Herein, we examine the role of iCCA TIME, highlighting its mechanisms, current applications and challenges, and future research directions. Treatment options for intrahepatic cholangiocarcinoma (iCCA), a highly malignant tumor with poor prognosis, are limited. Recent developments in immunotherapy and immune checkpoint inhibitors (ICIs) have offered new hope for treating iCCA. However, several issues remain, including the identification of reliable biomarkers of response to ICIs and immune-based combinations. Tumor immune microenvironment (TIME) of these hepatobiliary tumors has been evaluated and is under assessment in this setting in order to boost the efficacy of ICIs and to convert these immunologically "cold" tumors to "hot" tumors. Herein, the review TIME of ICCA and its critical function in immunotherapy. Moreover, this paper also discusses potential avenues for future research, including novel targets for immunotherapy and emerging treatment plans aimed to increase the effectiveness of immunotherapy and survival rates for iCCA patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report

Author

Palmerini, Emanuela, primary, Frega, Giorgio, additional, Gambarotti, Marco, additional, Frisoni, Tommaso, additional, Cesari, Marilena, additional, Bazzocchi, Alberto, additional, Miceli, Marco, additional, Donati, Davide Maria, additional, Fanti, Stefano, additional, Nanni, Cristina, additional, Benini, Stefania, additional, Longhi, Alessandra, additional, Paioli, Anna, additional, Marrari, Andrea, additional, Hakim, Rossella, additional, Righi, Alberto, additional, and Ibrahim, Toni, additional

Published
2023
Full Text
View/download PDF

13. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis

Author

Química orgánica I, Kimika organikoa I, Frega, Giorgio, Cossío Mora, Fernando Pedro, Bañales Asurmendi, Jesús María, Cardinale, Vincenzo, Macias, Rocio I. R., Braconi, Chiara, Lamarca, Angela, Química orgánica I, Kimika organikoa I, Frega, Giorgio, Cossío Mora, Fernando Pedro, Bañales Asurmendi, Jesús María, Cardinale, Vincenzo, Macias, Rocio I. R., Braconi, Chiara, and Lamarca, Angela

Abstract

Background: Immunotherapy has recently been incorporated into the spectrum of biliary tract cancer (BTC) treatment. The identification of predictive response biomarkers is essential in order to identify those patients who may benefit most from this novel treatment option. Here, we propose a systematic literature review and a meta-analysis of PD-1, PD-L1, and other immune-related biomarker expression levels in patients with BTC. Methods: Prisma guidelines were followed for this systematic review and meta-analysis. Eligible studies were searched on PubMed. Studies published between 2017 and 2022, reporting data on PD-1/PD-L1 expression and other immune-related biomarkers in patients with BTC, were considered eligible. Results: A total of 61 eligible studies were identified. Despite the great heterogeneity between 39 studies reporting data on PD-L1 expression, we found a mean PD-L1 expression percentage (by choosing the lowest cut-off per study) of 25.6% (95% CI 21.0 to 30.3) in BTCs. The mean expression percentages of PD-L1 were 27.3%, 21.3%, and 27.4% in intrahepatic cholangiocarcinomas (iCCAs—15 studies), perihilar–distal CCAs (p/dCCAs—7 studies), and gallbladder cancer (GBC—5 studies), respectively. Furthermore, 4.6% (95% CI 2.38 to 6.97) and 2.5% (95% CI 1.75 to 3.34) of BTCs could be classified as TMB-H and MSI/MMRd tumors, respectively. Conclusion: From our analysis, PD-L1 expression was found to occur approximately in 26% of BTC patients, with minimal differences based on anatomical location. TMB-H and MSI molecular phenotypes occurred less frequently. We still lack a reliable biomarker, especially in patients with mismatch-proficient tumors, and we must need to make an effort to conceive new prospective biomarker discovery studies.

Published
2023

14. The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma

Author

Palloni, Andrea, primary, Bisello, Silvia, additional, Maggio, Ilaria, additional, Massucci, Maria, additional, Galuppi, Andrea, additional, Di Federico, Alessandro, additional, Rizzo, Alessandro, additional, Ricci, Angela Dalia, additional, Siepe, Giambattista, additional, Morganti, Alessio Giuseppe, additional, Brandi, Giovanni, additional, and Frega, Giorgio, additional

Published
2023
Full Text
View/download PDF

17. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study

Author

Rizzo, Alessandro, primary, Salati, Massimiliano, additional, Frega, Giorgio, additional, Merz, Valeria, additional, Caputo, Francesco, additional, Di Federico, Alessandro, additional, Palloni, Andrea, additional, Carloni, Riccardo, additional, Ricci, Angela Dalia, additional, Gadaleta-Caldarola, Gennaro, additional, Messina, Carlo, additional, Spallanzani, Andrea, additional, Gelsomino, Fabio, additional, Benatti, Stefania, additional, Luppi, Gabriele, additional, Melisi, Davide, additional, Dominici, Massimo, additional, and Brandi, Giovanni, additional

Published
2022
Full Text
View/download PDF

18. Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center

Author

Rizzo, Alessandro, primary, Carloni, Riccardo, additional, Frega, Giorgio, additional, Palloni, Andrea, additional, Di Federico, Alessandro, additional, Ricci, Angela Dalia, additional, De Luca, Raffaele, additional, Tavolari, Simona, additional, and Brandi, Giovanni, additional

Published
2022
Full Text
View/download PDF

19. Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study

Author

Palmerini, Emanuela, primary, Pazzaglia, Laura, additional, Cevolani, Luca, additional, Pratelli, Loredana, additional, Pierini, Michela, additional, Quattrini, Irene, additional, Carretta, Elisa, additional, Manara, Maria Cristina, additional, Pasello, Michela, additional, Frega, Giorgio, additional, Paioli, Anna, additional, Longhi, Alessandra, additional, Cesari, Marilena, additional, Hakim, Rossella, additional, Ibrahim, Toni, additional, Campanacci, Laura, additional, Staals, Eric Lodewijk, additional, Donati, Davide Maria, additional, Benassi, Maria Serena, additional, Scotlandi, Katia, additional, and Ferrari, Stefano, additional

Published
2022
Full Text
View/download PDF

20. Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes

Author

Di Federico, Alessandro, primary, Mosca, Mirta, additional, Pagani, Rachele, additional, Carloni, Riccardo, additional, Frega, Giorgio, additional, De Giglio, Andrea, additional, Rizzo, Alessandro, additional, Ricci, Dalia, additional, Tavolari, Simona, additional, Di Marco, Mariacristina, additional, Palloni, Andrea, additional, and Brandi, Giovanni, additional

Published
2022
Full Text
View/download PDF

22. Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy

Author

Rimini, Margherita, primary, Casadei-Gardini, Andrea, additional, Brandi, Giovanni, additional, Leone, Francesco, additional, Fornaro, Lorenzo, additional, Pella, Nicoletta, additional, Silvestris, Nicola, additional, Montagnani, Francesco, additional, Lonardi, Sara, additional, Lai, Eleonora, additional, Galizia, Eva, additional, Santini, Daniele, additional, Palloni, Andrea, additional, Filippi, Roberto, additional, Masi, Gianluca, additional, Aprile, Giuseppe, additional, Aglietta, Massimo, additional, Frega, Giorgio, additional, Fenocchio, Elisabetta, additional, Vivaldi, Caterina, additional, Satolli, Maria Antonietta, additional, Salani, Francesca, additional, Scartozzi, Mario, additional, Faloppi, Luca, additional, Pellino, Antonio, additional, Sperti, Elisa, additional, Burgio, Valentina, additional, Ratti, Francesca, additional, Aldrighetti, Luca, additional, Cascinu, Stefano, additional, and Cucchetti, Alessandro, additional

Published
2022
Full Text
View/download PDF

23. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study

Author

Salati, Massimiliano, primary, Rizzo, Alessandro, additional, Merz, Valeria, additional, Messina, Carlo, additional, Francesco, Caputo, additional, Gelsomino, Fabio, additional, Spallanzani, Andrea, additional, Ricci, Angela Dalia, additional, Palloni, Andrea, additional, Frega, Giorgio, additional, De Lorenzo, Stefania, additional, Carotenuto, Pietro, additional, Pettorelli, Elisa, additional, Benatti, Stefania, additional, Luppi, Gabriele, additional, Melisi, Davide, additional, Brandi, Giovanni, additional, and Dominici, Massimo, additional

Published
2021
Full Text
View/download PDF

25. Caloric Restriction Mimetics, Autophagy, and Anticancer Immunosurveillance. ���The bacterial metabolite prodigiosin inhibits autophagy and suppresses antitumor immunity. Results from a fluorescent biosensor-based screening of bacterial metabolites���

Author

Frega, Giorgio <1986> and Brandi, Giovanni

Subjects
MED/06 Oncologia medica
Abstract

Nutrition plays a crucial role in the development and progression of different types of cancer. Dietary components, as well as gut microbiota-derived factors, can exert metabolic and immunomodulatory functions on the host, both locally and systemically. Recent studies highlighted the role of specific gut microbes as predictors of response to immunotherapy. Autophagy has a key function in the elicitation of an immune in response to anticancer therapy. Here, we conducted an automatized fluorescent biosensor-based screening to identify autophagy modulators from a chemical library of host- and bacteria-derived metabolites and found prodigiosin, a red pigment produced by Serratia marcescens, as a potent inducer of LC3 dots in GFP-LC3 biosensor cells. Further autophagic flux analysis in RFP-GFP-LC3 tandem reporter cells and a GFP-Q74 Huntington’s disease model revealed that prodigiosin acts as an inhibitor of autophagic flux. Consistent with the described immunosuppressive role of prodigiosin, our in vivo experiment in BALB/c mice transplanted with syngeneic colon cancers suggest that prodigiosin impairs the activity of anti-PD1 immunotherapy.

Published
2021
Full Text
View/download PDF

28. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis

Author

Filippi, Roberto, primary, Leone, Francesco, additional, Fornaro, Lorenzo, additional, Aprile, Giuseppe, additional, Casadei-Gardini, Andrea, additional, Silvestris, Nicola, additional, Palloni, Andrea, additional, Satolli, Maria Antonietta, additional, Scartozzi, Mario, additional, Russano, Marco, additional, Lutrino, Stefania Eufemia, additional, Lombardi, Pasquale, additional, Frega, Giorgio, additional, Garattini, Silvio Ken, additional, Vivaldi, Caterina, additional, Spadi, Rosella, additional, Giulia, Orsi, additional, Fenocchio, Elisabetta, additional, Brunetti, Oronzo, additional, Aglietta, Massimo, additional, and Brandi, Giovanni, additional

Published
2021
Full Text
View/download PDF

29. Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

Author

Di Federico, Alessandro, primary, Tateo, Valentina, additional, Parisi, Claudia, additional, Formica, Francesca, additional, Carloni, Riccardo, additional, Frega, Giorgio, additional, Rizzo, Alessandro, additional, Ricci, Dalia, additional, Di Marco, Mariacristina, additional, Palloni, Andrea, additional, and Brandi, Giovanni, additional

Published
2021
Full Text
View/download PDF

31. Caloric Restriction Mimetics, Autophagy, and Anticancer Immunosurveillance. “The bacterial metabolite prodigiosin inhibits autophagy and suppresses antitumor immunity. Results from a fluorescent biosensor-based screening of bacterial metabolites”

Author

Brandi, Giovanni, Frega, Giorgio <1986>, Brandi, Giovanni, and Frega, Giorgio <1986>

Abstract

Nutrition plays a crucial role in the development and progression of different types of cancer. Dietary components, as well as gut microbiota-derived factors, can exert metabolic and immunomodulatory functions on the host, both locally and systemically. Recent studies highlighted the role of specific gut microbes as predictors of response to immunotherapy. Autophagy has a key function in the elicitation of an immune in response to anticancer therapy. Here, we conducted an automatized fluorescent biosensor-based screening to identify autophagy modulators from a chemical library of host- and bacteria-derived metabolites and found prodigiosin, a red pigment produced by Serratia marcescens, as a potent inducer of LC3 dots in GFP-LC3 biosensor cells. Further autophagic flux analysis in RFP-GFP-LC3 tandem reporter cells and a GFP-Q74 Huntington’s disease model revealed that prodigiosin acts as an inhibitor of autophagic flux. Consistent with the described immunosuppressive role of prodigiosin, our in vivo experiment in BALB/c mice transplanted with syngeneic colon cancers suggest that prodigiosin impairs the activity of anti-PD1 immunotherapy.

Published
2021

34. Second-line chemotherapy (2L) in elderly patients with advanced biliary tract cancer (ABC): A multicenter real-world study.

Author

Rizzo, Alessandro, primary, Salati, Massimiliano, additional, Frega, Giorgio, additional, Merz, Valeria, additional, Caputo, Francesco, additional, Ricci, Angela Dalia, additional, Palloni, Andrea, additional, Messina, Carlo, additional, Spallanzani, Andrea, additional, Saccoccio, Gioconda, additional, Mollica, Veronica, additional, Gelsomino, Fabio, additional, Benatti, Stefania, additional, Luppi, Gabriele, additional, Melisi, Davide, additional, Dominici, Massimo, additional, and Brandi, Giovanni, additional

Published
2021
Full Text
View/download PDF

39. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow

Author

RIZZO, ALESSANDRO, primary, RICCI, ANGELA DALIA, additional, TOBER, NASTASSJA, additional, NIGRO, MARIA CONCETTA, additional, MOSCA, MIRTA, additional, PALLONI, ANDREA, additional, ABBATI, FRANCESCA, additional, FREGA, GIORGIO, additional, DE LORENZO, STEFANIA, additional, TAVOLARI, SIMONA, additional, and BRANDI, GIOVANNI, additional

Published
2020
Full Text
View/download PDF

40. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.

Author

Filippi, Roberto, Leone, Francesco, Fornaro, Lorenzo, Aprile, Giuseppe, Casadei-Gardini, Andrea, Silvestris, Nicola, Palloni, Andrea, Satolli, Maria Antonietta, Scartozzi, Mario, Russano, Marco, Lutrino, Stefania Eufemia, Lombardi, Pasquale, Frega, Giorgio, Garattini, Silvio Ken, Vivaldi, Caterina, Spadi, Rosella, Giulia, Orsi, Fenocchio, Elisabetta, Brunetti, Oronzo, and Aglietta, Massimo

Published
2022
Full Text
View/download PDF

41. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.

Author

Salati, Massimiliano, Rizzo, Alessandro, Merz, Valeria, Messina, Carlo, Francesco, Caputo, Gelsomino, Fabio, Spallanzani, Andrea, Ricci, Angela Dalia, Palloni, Andrea, Frega, Giorgio, De Lorenzo, Stefania, Carotenuto, Pietro, Pettorelli, Elisa, Benatti, Stefania, Luppi, Gabriele, Melisi, Davide, Brandi, Giovanni, and Dominici, Massimo

Subjects
PROGNOSIS, TREATMENT effectiveness, PROPORTIONAL hazards models, GALLBLADDER cancer, KAPLAN-Meier estimator, MONOCYTE lymphocyte ratio
Abstract

Here, we aim at describing the pattern of care, survival outcome and prognostic factors of ABC patients (pts) receiving third-line chemotherapy. Institutional registries across three academic medical centers were retrospectively reviewed. Kaplan–Meier estimators were used to calculate survival, the log-rank test to make comparisons, and the Cox proportional hazard models to assess the progostic impact of variables. Among 101 pts included in the analysis. 68 (67.3%), 19 (18.8%) and 14 (13.8%) had intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer, respectively. Atotal of 63 (62.3%) pts received monochemotherapy, while 38 (37.6%) were treated with adoublet. The median OS and PFS were 5 and 3 months, respectively. Disease control rate was achieved in 23 (22.7%) pts, with 2 (2%) partial responses. Grade 3–4 treatment-related adverse events were reported in 22 (21.7%) pts. At multivariate analysis, ECOG PS (p < 0.001), tumor burden (p = 0.01) and lymphocyte-to-monocyte ratio (p =0.02) were independent predictors of survival. Third-line chemotherapy displayed limited activity in this real-world cohort, although prognostic factors have been identified that may assist in treatment decision. The results of this multicenter experience, highlight the need for more effective therapies and provide a benchmark for future trials in this setting. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience

Author

Brandi, Giovanni, primary, Rizzo, Alessandro, additional, Dall’Olio, Filippo Gustavo, additional, Felicani, Cristina, additional, Ercolani, Giorgio, additional, Cescon, Matteo, additional, Frega, Giorgio, additional, Tavolari, Simona, additional, Palloni, Andrea, additional, De Lorenzo, Stefania, additional, Abbati, Francesca, additional, Mollica, Veronica, additional, Ricci, Angela Dalia, additional, and Serra, Carla, additional

Published
2020
Full Text
View/download PDF

44. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma

Author

RICCI, ANGELA DALIA, primary, RIZZO, ALESSANDRO, additional, BONUCCI, CHIARA, additional, TAVOLARI, SIMONA, additional, PALLONI, ANDREA, additional, FREGA, GIORGIO, additional, MOLLICA, VERONICA, additional, TOBER, NASTASSJA, additional, MAZZOTTA, ELENA, additional, FELICANI, CRISTINA, additional, SERRA, CARLA, additional, and BRANDI, GIOVANNI, additional

Published
2020
Full Text
View/download PDF

47. How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis

Author

RIZZO, ALESSANDRO, primary, RICCI, ANGELA DALIA, additional, FREGA, GIORGIO, additional, PALLONI, ANDREA, additional, DE LORENZO, STEFANIA, additional, ABBATI, FRANCESCA, additional, MOLLICA, VERONICA, additional, TAVOLARI, SIMONA, additional, DI MARCO, MARIACRISTINA, additional, and BRANDI, GIOVANNI, additional

Published
2020
Full Text
View/download PDF

48. BAP1 in solid tumors

Author

Di Nunno, Vincenzo, primary, Frega, Giorgio, additional, Santoni, Matteo, additional, Gatto, Lidia, additional, Fiorentino, Michelangelo, additional, Montironi, Rodolfo, additional, Battelli, Nicola, additional, Brandi, Giovanni, additional, and Massari, Francesco, additional

Published
2019
Full Text
View/download PDF

50. Adjuvant treatment in biliary tract cancer

Author

Palloni, Andrea, primary, Frega, Giorgio, additional, De Lorenzo, Stefania, additional, Rizzo, Alessandro, additional, Abbati, Francesca, additional, Deserti, Marzia, additional, Tavolari, Simona, additional, and Brandi, Giovanni, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results